Navigation Links
Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents
Date:6/17/2009

ident and CEO of EthiX Associates, a pharmaceutical and biotech consultancy he founded in 1996. He has also served as the President and CEO of GenBioPro, Inc., a specialty biopharmaceutical company focused on the development and marketing of "biosimilar" products, and INSYS Therapeutics, Inc., a privately held biopharmaceutical company with a focus on chemotherapy induced nausea and vomiting, pain management and CNS disorders.

He held the positions of the Chairman, President, and CEO of the Arizona BioIndustry Association from 2004 to 2007.

Mr. McGarity was President and Chief Operating Officer and then Vice Chairman of Pharmaceutical Marketing Services, Inc. from 1991 to 1996.

He was employed by GlaxoSmithKline (then Glaxo) from 1987 to 1991. Over that time he served as Vice President in the Corporate Division; Vice President of National Accounts; Vice President and General Manager of the Glaxo Dermatology group; and Director of Managed Health Care.

From 1981 to 1986, Mr. McGarity worked as Vice President of Sales and Marketing at Westwood Pharmaceuticals, the specialty pharmaceuticals division of Bristol Myers Squibb.

From 1965 to 1981 he was employed by Novartis Pharmaceuticals (then Sandoz) having worked throughout the ranks of their commercial organization as a sales representative, hospital representative, product manager, district manager, and Director of Sales and Marketing in Canada and the United States.

Mr. McGarity is a Board Director at Cypress Biosciences Inc. (CYPB), and also serves on the Boards of several early stage pharma/biotech companies including Apthera, GenBioPro, SynBuild, MedApps, Inc., and Restorative Biosciences. He also sits of the Boards of a number of life science organizations and university programs including the Arizona BioIndustry Association and the Global Advisory Council at Thunderbird School of Global Management
'/>"/>

SOURCE Campbell Alliance
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY
2. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
3. Campbell Alliance Hires Joe Dillon, Expands Business Development Practice
4. Campbell Alliance Sales Practice to Present at CBIs Leadership Summit on Evolving the Pharma Sales Model
5. Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
6. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
7. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
8. Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting
9. Campbell Alliance Trade and Distribution Practice to Speak at CBIs Commercial Contracts and Chargeback Management Conference
10. Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference
11. Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... a privately held company based in ... a big data platform for centralized management and ... proprietary on-market Genomic Management Solution, Bina-GMS 1 , ... fast and scalable analyses to maximize the value ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... LLC , a software company in Waukesha that sells home ... programs, said on Thursday it has been acquired by a ... it would expand its offerings to manufacturers and retailers by ... and product pictures. Big Hammer operates one of 11 authorized ...
... In the same week that state senators in Wisconsin ... to include ethanol, policymakers in another Midwestern state were ... , ,Agri-business giant Louis Dreyfus Corp. announced it ... northern Indiana, where it plans to crush nearly 50 ...
... company in central Wisconsin has announced its plans ... offerings of high-speed Internet and voice over IP services. ... serves about 28,000 customers. CEO Douglas Wenzlaff told reporters ... Madison and Eau Claire. Its existing base is in ...
Cached Biology Technology:Ethanol bill's death in Wisconsin ignores what's happening with our neighbors 2Ethanol bill's death in Wisconsin ignores what's happening with our neighbors 3
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... in those green coffee bean dietary supplements often touted ... obese laboratory mice fed a high-fat diet when given at ... in ACS, Journal of Agricultural and Food Chemistry . ... fat in the liver. Vance Matthews, Kevin Croft ...
... 2013: A new study presented today at EULAR 2013, ... shows that one in eight patients at risk of ... over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat ... NSAID users, over one-third had taken the medication for ...
... show ways in which we can markedly improve drug targeting ... imaging techniques. In real time and in three dimensions, ... active cancer cells respond to a particular drug. They can ... to administer drugs. Finally, using preclinical models of the disease, ...
Cached Biology News:Patients use OTC NSAIDs even when they have a high risk of serious side effects 2Nanotechnology helps track and improve drug action in pancreatic cancer 2
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Human BMP 2 Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
... Imaging's proprietary Focus™ detector technology, while precisily ... R4. The microPET Focus 120 offers ... PET scanner. Focus scanners also possess ... based PETsystems. The combination of high ...
... This product has been developed to ... peroxidase labeled proteins. Stability is increased ... to 2-8 centigrade. This product is ... no mercury or azide. This formulation ...
Biology Products: